BC
EDIT icon

Bridgefront Capital’s Editas Medicine EDIT Stock Holding History

Bridgefront Capital’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,954
Closed -$51.2K – 583
2024
Q2 		$51.2K Buy
+10,954
New +$61.8K 0.02% 465
2023
Q3 		– Sell
-53,320
Closed -$439K – 445
2023
Q2 		$439K Buy
53,320
+22,601
+74% +$197K 0.24% 146
2023
Q1 		$223K Buy
+30,719
New +$273K 0.14% 307
2021
Q2 		– Sell
-6,554
Closed -$275K – 672
2021
Q1 		$275K Buy
6,554
+732
+13% +$41.7K 0.09% 458
2020
Q4 		$408K Buy
+5,822
New +$239K 0.14% 273

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bridgefront Capital's EDIT Position: Q3 2024 in Review

Bridgefront Capital sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 10,954 shares — an estimated $51.2K sold.

Bridgefront Capital first reported a position in EDIT in Q4 2020 and held it in 5 quarters. The position peaked at $439K in Q2 2023. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Bridgefront Capital reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Bridgefront Capital sold 10,954 Editas Medicine shares in Q3 2024, an estimated $51.2K.
  • Bridgefront Capital first reported a position in Editas Medicine in Q4 2020 and held it in 5 quarters.
  • Bridgefront Capital's Editas Medicine position peaked at $439K in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Bridgefront Capital's 13F filing for Q3 2024, filed 14 Nov 2024.